HK1136211A1 - Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage - Google Patents

Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage

Info

Publication number
HK1136211A1
HK1136211A1 HK10103057.2A HK10103057A HK1136211A1 HK 1136211 A1 HK1136211 A1 HK 1136211A1 HK 10103057 A HK10103057 A HK 10103057A HK 1136211 A1 HK1136211 A1 HK 1136211A1
Authority
HK
Hong Kong
Prior art keywords
repair
tissue damage
cell derived
stromal cell
derived factor
Prior art date
Application number
HK10103057.2A
Other languages
English (en)
Chinese (zh)
Inventor
Richard T Lee
Vincent Segers
Original Assignee
Brigham & Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital Inc filed Critical Brigham & Womens Hospital Inc
Publication of HK1136211A1 publication Critical patent/HK1136211A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
HK10103057.2A 2006-10-23 2010-03-23 Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage HK1136211A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85344106P 2006-10-23 2006-10-23
US92935307P 2007-06-22 2007-06-22
US11/976,032 US7696309B2 (en) 2006-10-23 2007-10-19 Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
PCT/US2007/022394 WO2008051505A2 (fr) 2006-10-23 2007-10-22 Mutants résistants aux protéases du facteur dérivé des cellules stromales de type 1 utilisés dans la réparation d'une lésion tissulaire

Publications (1)

Publication Number Publication Date
HK1136211A1 true HK1136211A1 (en) 2010-06-25

Family

ID=39318162

Family Applications (2)

Application Number Title Priority Date Filing Date
HK10103057.2A HK1136211A1 (en) 2006-10-23 2010-03-23 Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
HK15105619.3A HK1205139A1 (en) 2006-10-23 2015-06-15 Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15105619.3A HK1205139A1 (en) 2006-10-23 2015-06-15 Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage

Country Status (10)

Country Link
US (6) US7696309B2 (fr)
EP (2) EP2676674B1 (fr)
JP (2) JP5695318B2 (fr)
CN (2) CN101553243B (fr)
AU (1) AU2007309479A1 (fr)
CA (1) CA2667280C (fr)
HK (2) HK1136211A1 (fr)
IL (2) IL198021A (fr)
NZ (1) NZ576188A (fr)
WO (1) WO2008051505A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260258A1 (en) * 2003-12-18 2005-11-24 The Texas A&M University System Use of vitelline protein B as a microencapsulating additive
US7696309B2 (en) 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
CA2754072C (fr) 2009-03-02 2019-01-15 Massachusetts Institute Of Technology Procedes et produits pour etablir un profil enzymatique in vivo
US9308277B2 (en) * 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US8741833B2 (en) * 2010-07-16 2014-06-03 Massachusetts Institute Of Technology Self-assembling peptides incorporating modifications and methods of use thereof
WO2012027170A1 (fr) * 2010-08-23 2012-03-01 Provasculon, Inc. Méthodes de réparation de lésions tissulaires faisant appel à des mutants résistants aux protéases du facteur dérivé des cellules stromales de type 1
JP6245990B2 (ja) 2011-03-15 2017-12-13 マサチューセッツ インスティテュート オブ テクノロジー 同位体によりコード化されたレポーターによる多重検出
EP2717894B1 (fr) * 2011-06-07 2018-01-24 Mesoblast International Sàrl Procédés de réparation de dommage tissulaire à l'aide de mutants résistant aux protéases du facteur 1 dérivé de cellules stromales
CN102660570B (zh) * 2012-05-10 2014-05-14 江南大学 一种提高酶热稳定性的方法
CN118010994A (zh) 2013-06-07 2024-05-10 麻省理工学院 基于亲和力检测配体编码的合成性生物标记物
KR20160096640A (ko) * 2013-12-13 2016-08-16 메조블라스트 인터내셔널 에스에이알엘 기질 세포 유래 인자-1의 프로테아제-내성 돌연변이를 사용한 조직 손상의 복구 방법
CN104650192B (zh) * 2015-03-26 2017-06-23 罗忠礼 一类能用于修复子宫和保护心肌的自组装短肽及其应用
EP3440013A4 (fr) 2016-04-08 2021-03-17 Massachusetts Institute of Technology Procédés pour profiler spécifiquement l'activité de la protéase au niveau de ganglions lymphatiques
US11428689B2 (en) 2016-05-05 2022-08-30 Massachusetts Institute Of Technology Methods and uses for remotely triggered protease activity measurements
EP3607085A1 (fr) 2017-04-07 2020-02-12 Massachusetts Institute Of Technology Procédés de profilage spatial d'activité protéase dans un tissu et des coupes
US11054428B2 (en) 2018-03-05 2021-07-06 Massachusetts Institute Of Technology Inhalable nanosensors with volatile reporters and uses thereof
CN109234339B (zh) * 2018-11-22 2020-12-29 湖南汇升生物科技有限公司 一种高纯度结晶麦芽糖的生产方法
CN109321481B (zh) * 2018-11-22 2020-12-29 湖南汇升生物科技有限公司 一种生麦芽糖淀粉酶生产菌株
CN109486792B (zh) * 2018-11-22 2019-12-10 湖南汇升生物科技有限公司 一种生麦芽糖淀粉酶突变体的制备及其应用
CN109439641B (zh) * 2018-11-22 2020-12-29 湖南汇升生物科技有限公司 一种生麦芽糖淀粉酶生产菌株的应用
EP3892330A4 (fr) * 2018-12-04 2022-10-26 Chugai Seiyaku Kabushiki Kaisha Ligand de cxcr3
US11835522B2 (en) 2019-01-17 2023-12-05 Massachusetts Institute Of Technology Sensors for detecting and imaging of cancer metastasis

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69207607T3 (de) * 1991-11-13 2006-07-06 T.A.C. Thrombosis And Coagulation Ab Verfahren zur diagnose von störungen der blutgerinnung
US5670483A (en) * 1992-12-28 1997-09-23 Massachusetts Insititute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
CA2117953C (fr) * 1993-10-14 2001-12-11 Tasuku Honjo Derive de la stromale humaine facteur 1 aplha et 1 beta et adn encodant ceux-ci
JP3329109B2 (ja) * 1994-12-02 2002-09-30 ソニー株式会社 プラズマアドレス表示装置
US6852508B1 (en) * 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US6214540B1 (en) * 1997-03-26 2001-04-10 University Of Maryland Biotechnology Institute Chemokines that inhibit immunodeficiency virus infection and methods based thereon
EP1061944B1 (fr) * 1998-03-13 2004-01-28 The University Of British Columbia Antagonistes therapeutiques du recepteur de chemokine
CA2305787A1 (fr) * 2000-05-09 2001-11-09 The University Of British Columbia Traitement antagoniste cxcr4 de cellules hematopoietiques
CA2245224A1 (fr) * 1998-08-14 2000-02-14 Jiang-Hong Giong Antagonistes du recepteur de la chimiokine et chimiotherapie
US20020107196A1 (en) * 1998-07-21 2002-08-08 Smithkline Beecham Corporation Method for inducing chemotaxis in endothelial cells by administering stromal cell derived factor-1alpha
US6221856B1 (en) * 1999-02-03 2001-04-24 Inologic, Inc. Inositol derivatives for inhibiting superoxide anion production
US20050059584A1 (en) * 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
US7368425B2 (en) 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
US7378098B2 (en) * 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
CA2335109A1 (fr) * 2000-04-12 2001-10-12 Chemokine Therapeutics Corporation Traitement de cellules hematopoietiques avec des agonistes du cxcr4
DE10027383A1 (de) * 2000-06-02 2001-12-20 Rhein Biotech Proz & Prod Gmbh Nukleinsäure-Molekül umfassend eine für ein Chemokin, einen Neuropeptid-Präkursor oder mindestens ein Neuropeptid kodierende Nukleinsäuresequenz
MXPA02012067A (es) 2000-06-05 2004-08-19 Univ Columbia Identificacion y uso de celulas endoteliales precursoras derivadas de medula osea par mejorar la funcion del miocardio despues de dano isquemico.
US7547674B2 (en) 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
WO2002036078A2 (fr) * 2000-11-05 2002-05-10 University Of Florida Ciblage de cellules souches pluripotentielles dans des tissus
WO2002038172A2 (fr) 2000-11-09 2002-05-16 Genetics Institute, Llc VACCINS TUMORAUX SDF-1β ET UTILISATIONS CORRESPONDANTES
CA2430401A1 (fr) * 2000-12-01 2002-06-06 Schering Corporation Utilisation de genes et reactifs associes
WO2002045717A1 (fr) * 2000-12-06 2002-06-13 Tularik Inc. Polytherapie a base de lometrexol
WO2003046833A2 (fr) * 2001-11-24 2003-06-05 Image Analysis, Inc. Detection et quantification automatiques de calcium coronarien et de calcium aortique
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
AU2003240614A1 (en) * 2002-05-10 2003-11-11 Ipf Pharmaceuticals Gmbh A method of inhibiting the emigration of cells from the intravascular compartment into tissues
US7485141B2 (en) * 2002-05-10 2009-02-03 Cordis Corporation Method of placing a tubular membrane on a structural frame
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
US20040037811A1 (en) 2002-08-22 2004-02-26 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
CN100366257C (zh) * 2002-08-22 2008-02-06 克里夫兰诊所基金会 基质细胞衍生因子-1介导缺血性心肌病中干细胞归巢及组织再生
EP1546181A2 (fr) * 2002-08-23 2005-06-29 Bristol-Myers Squibb Company Procedes de reduction de lesions ischemiques
US20070060512A1 (en) * 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
WO2004094465A2 (fr) 2003-04-23 2004-11-04 The Board Of Trustees Of The University Of Illinois Office Of Technology Management University Of Illinois At Urbana-Champaign Molecules synthetiques imitant les chimiokines
CN1252089C (zh) * 2003-09-16 2006-04-19 广州润兴生物科技有限公司 基质细胞衍生因子－1α重组突变体的构建和制备
US7776564B2 (en) 2004-04-30 2010-08-17 Five Prime Therapeutics, Inc. Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use
EP1803464A4 (fr) * 2004-09-17 2009-09-09 Cellgentech Inc Preparation externe pour le traitement des ulceres cutanes
KR20160028498A (ko) * 2004-09-24 2016-03-11 메소블라스트, 아이엔씨. 간엽 전구세포의 증식 및/또는 생존성 증강 방법
WO2006047315A2 (fr) * 2004-10-25 2006-05-04 The Brigham And Women's Hospital, Inc. Administration ciblee de facteurs biologiques au moyen de nanofibres peptidiques a auto-assemblage
US20060110374A1 (en) 2004-11-24 2006-05-25 Dudy Czeiger Method to accelerate stem cell recruitment and homing
JP2008526749A (ja) * 2005-01-04 2008-07-24 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド 自己アセンブリするペプチドナノファイバーを用いたｐｄｇｆの徐放性の送達
WO2006074464A2 (fr) 2005-01-10 2006-07-13 Mayo Foundation For Medical Education And Research Modulation de l'activite du recepteur de type toll
EP1879606B1 (fr) * 2005-04-25 2013-06-12 Massachusetts Institute of Technology Peptides autoassembleurs pour favoriser l'hémostase
CN101300031A (zh) * 2005-10-31 2008-11-05 雪兰诺实验室有限公司 用sdf-1治疗和/或预防神经疾病
WO2007079460A2 (fr) 2006-01-04 2007-07-12 Chemokine Therapeutics Corporation Conception d'analogues de chimiokines cxc pour le traitement de maladies humaines
US7696309B2 (en) 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US20080194478A1 (en) * 2007-02-09 2008-08-14 Gene Signal International Sa Wound healing agent and composition
US20110159099A1 (en) * 2008-08-26 2011-06-30 National University Corporation, Hokkaido University Bone-filling type agent for inducing cartilage regeneration
WO2010135570A1 (fr) * 2009-05-20 2010-11-25 Board Of Regents, The University Of Texas System Identification de micro-arn impliqués dans un remodelage post-infarctus du myocarde et une insuffisance cardiaque

Also Published As

Publication number Publication date
IL231752A0 (en) 2014-05-28
CA2667280A1 (fr) 2008-05-02
AU2007309479A1 (en) 2008-05-02
CN104211800B (zh) 2019-02-01
EP2094288A2 (fr) 2009-09-02
US20210246182A1 (en) 2021-08-12
EP2676674A1 (fr) 2013-12-25
HK1205139A1 (en) 2015-12-11
IL198021A0 (en) 2011-08-01
WO2008051505A3 (fr) 2008-11-27
NZ576188A (en) 2012-10-26
US10774124B2 (en) 2020-09-15
US9631005B2 (en) 2017-04-25
JP2010507391A (ja) 2010-03-11
US20220009984A9 (en) 2022-01-13
US20170101451A1 (en) 2017-04-13
US20110269685A1 (en) 2011-11-03
US20100184950A1 (en) 2010-07-22
CA2667280C (fr) 2015-12-01
CN104211800A (zh) 2014-12-17
IL198021A (en) 2014-11-30
WO2008051505A8 (fr) 2008-10-02
WO2008051505A2 (fr) 2008-05-02
EP2676674B1 (fr) 2017-06-21
US7696309B2 (en) 2010-04-13
US20080095758A1 (en) 2008-04-24
US7999067B2 (en) 2011-08-16
EP2094288A4 (fr) 2010-09-08
CN101553243B (zh) 2014-08-27
AU2007309479A2 (en) 2009-05-14
JP2015057058A (ja) 2015-03-26
US20140024595A1 (en) 2014-01-23
CN101553243A (zh) 2009-10-07
JP5695318B2 (ja) 2015-04-01

Similar Documents

Publication Publication Date Title
HK1205139A1 (en) Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
GB2424118B (en) Fuel cells
EP2029049A4 (fr) Procédés et compositions pour réparation tissulaire
GB2440434B (en) Fuel cells
GB0605878D0 (en) Fuel cells
PL1957633T3 (pl) Immunomodulacja z zastosowaniem komórek macierzystych łożyska
EP2005504A4 (fr) Electrolyte
GB0608079D0 (en) Fuel cells
EP2038379A4 (fr) Biodiesel vert
GB0614337D0 (en) Fuel Cells
IL195826A0 (en) Placental niche and use thereof to culture stem cells
IL193721A0 (en) Polypeptide producing cells
HK1134835A1 (en) Methods for increasing and mobilizing hematopoietic stem cells
IL196913A0 (en) Suppressor trna transcription in vertebrate cells
GB2426452B (en) Tissue repair
GB0610414D0 (en) Tissue repair
EP1863113A4 (fr) Pile a combustible
ZA200805081B (en) In vivo cell surface engineering
EP1873855A4 (fr) Pile a combustible
GB0606671D0 (en) Cell Culture
EP1865568A4 (fr) Pile a combustible
EP1885012A4 (fr) Pile à combustible
EP1941890A4 (fr) Proliferateur de cellules souches hematopoietiques
GB0511723D0 (en) Placental stem cells
EP1848052A4 (fr) Pile a combustible